Drug interactions with cannabinoids
Authors:
- 2 March 2020
- journal article
- editorial
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 192 (9) , E206
Abstract
Cannabidiol inhibits CYP2C19, increasing levels of the active metabolite of clobazam threefold.1,3 Interactions with other drugs metabolized by CYP2C19 (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.191097/-/DC1) should be anticipated. Very high international normalized ratio levels and bleeding have been reported with combined used of warfarin and marijuana.1 A case reporting a threefold increase in tacrolimus levels following the addition of cannabidiol shows that CYP3A4/5 inhibition can also occur.4Keywords
This publication has 5 references indexed in Scilit:
- Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimusAmerican Journal of Transplantation, 2019
- A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokineticsPharmacology & Therapeutics, 2019
- The pharmacokinetics and the pharmacodynamics of cannabinoidsBritish Journal of Clinical Pharmacology, 2018
- Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsyEpilepsia, 2015
- A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteersSpringerPlus, 2013